XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 53.82

Change

+0.66 (+1.24)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.13 (-0.47%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.39 (+0.78%)

USD 112.00B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 98.90B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.26 (-0.47%)

USD 92.14B
SXRZ:F iShares VII PLC - iShares Nikk..

+3.25 (+1.39%)

USD 57.35B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.09 (-0.57%)

USD 53.27B
VUSA:F Vanguard Funds Public Limited ..

-0.65 (-0.64%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.94 (-0.92%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.02 (-0.21%)

USD 40.47B
0ZC:F Zscaler Inc

-2.88 (-1.64%)

USD 37.92B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.27% 56% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.27% 54% F 55% F
Trailing 12 Months  
Capital Gain 11.31% 55% F 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.31% 52% F 55% F
Trailing 5 Years  
Capital Gain 70.99% 83% B 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.99% 82% B 63% D
Average Annual (5 Year Horizon)  
Capital Gain 10.75% 84% B 77% C+
Dividend Return 10.75% 83% B 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.72% 58% F 81% B-
Risk Adjusted Return 100.23% 98% N/A 97% N/A
Market Capitalization 0.85B 70% C- 56% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike